Acute and chronic anti-ischemic actions of pranidipine in three animal models

Asia Pacific Journal of Pharmacology

Volumn 16, Issue 1, 2003, Pages 29-37

  Takase, H ^a   Kovanecz, I ^b   Mori, T ^a   Ohura, M ^a   Fujiki, H ^a   Yoshida, K ^a   Sumida, T ^a   Tominaga, M ^a   Papp, J G ^b   Szekeres, L ^b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

"Test" stress; Anti ischemic; Arginine vasopressin; Coronary blood flow; Endothelin 1; Pranidipine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ISOPRENALINE; PHENYLEPHRINE; PRANIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; DOSE TIME EFFECT RELATION; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART RATE; MALE; NONHUMAN; PROVOCATION TEST; RABBIT; RAT; REPRODUCIBILITY; ST SEGMENT DEPRESSION;

EID: 0038334926     PISSN: 02179687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Robertson MR, Robertson D. Drugs used for the treatment of myocardial ischemia. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. Goodman & Gilman's The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill 1996: 759-79.
2. Nakayama N, Ikezono K, Mori T, Yamashita S, Nakayama S, Tanaka Y, Hosokawa T, Minami Y, Masutani K, Yamamura Y, Yabuuchi Y. Antihypertensive activity of OPC-13340, a new potent and long-acting dihydropyridine calcium antagonist, in rats. Journal of Cardiovascular Pharmacology 1990; 15: 836-44.
3. Mori T, Nakayama N, Ohura M, Ikezono K, Kinoshita S, Kamata M, Hosokawa T, Yamashita S, Yabuuchi Y. Cardiovascular effects of OPC-13340, a potent, long-acting 1,4-dihydropyridine calcium channel blocker, in dogs. Archives Internationales de Pharmacodynamie et de 1993; 321: 41-56.
4. Broadhurst P, Brigden G, Hittel N, Lahiri A, Raftery EB. Prolonged hypotensive effect of OPC-13340: a new, once-daily calcium channel blocking drug. European Heart Journal 1991; 12: 434-8.
5. Tominaga M, Tsuchihashi T, Kinoshita H, Kobayashi K, Ohya Y, Abe I, Takata Y, Fujishima M. Ambulatory blood pressure monitoring in elderly hypertensives treated with the new calcium antagonist, pranidipine (OPC-13340). International Journal of Clinical Pharmacology and Therapeutics 1995; 33: 277-80.
6. Rosenthal J, Hittel N, Stumpe KO. Pranidipine, a novel calcium antagonist, once daily, for the treatment of hypertension: a multicenter, double-blind, placebocontrolled dose finding study. Cardiovascular Drugs and Therapy 1996; 10: 59-66.
7. Ohura M, Mori T, Watanabe K, Ikezono K, Nakayama N, Tominaga M, Yabuuchi Y. Effects of pranidipine (OPC-13340), a novel 1,4-dihydropyridine derivative Ca-antagonist, on isolated porcine coronary contraction and acute myocardial ischemia in the pig. Folia Pharmacologica Japonica 1994; 103: 101-9. (In Japanese)
8. Nishinaka Y, Yokota M, Watanabe M, Sobue T, Iwase M, Ukai M, Ando A, Nagata K, Saito H. Hemodynamic effects of the calcium channel blocker pranidipine on exercise-induced angina. International Journal of Clinical Pharmacology and Therapeutics 1994; 32: 542-9.
9. Igarashi Y, Aizawa Y, Tamura M, Ebe K, Yamaguchi T, Shibata A. Vasoconstrictor effect of endothelin on the canine coronary artery: is a novel endogenous peptide involved in regulating myocardial blood flow and coronary spasm? American Heart Journal 1989; 118: 674-8.
10. Sakuma I, Asajima H, Fukao M, Tohse N, Tamura M, Kitabatake A. Effects of BQ-485, a selective ETA antagonist, on endothelin-mediated vasomotion in rat coronary vascular beds. Journal of Cardiovascular Pharmacology 1995; 26 (Supplement III): S400-S403.
11. Gutstein WH, Anversa P, Beghi C, Kiu G, Pacanovsky D. Coronary artery spasm in the rat induced by hypothalamic stimulation. Atherosclerosis 1984; 51: 135-42.
12. Maturi MF, Martin SE, Markle D, Maxwell M, Burruss CR, Speir E, Greene R, Ro YM, Vitale D, Green MV. Coronary vasoconstriction induced by vasopressin. Production of myocardial ischemia in dogs by constriction of nondiseased small vessels. Circulation 1991; 83: 2111-21.
13. Emori T, Hirata Y, Ohta K, Kanno K, Eguchi S, Imai T, Shichiri M, Marumo F. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991; 18: 165-70.
14. Artigou JY, Salloum J, Carayon A, Lechat P, Maistre G, Isnard R, Komajda M, Legrand JC, Grosgogeat Y. Variations in plasma endothelin concentrations during coronary spasm. European Heart Journal 1993; 14: 780-4.
15. Toyo-oka T, Aizawa T, Suzuki N, Hirata Y, Miyauchi T, Shin WS, Yanagisawa M, Masaki T, Sugimoto T. Increased plasma level of endothelin-1 and coronary spasm induction in patients with vasospastic angina pectoris. Circulation 1991; 83: 476-83.
16. Kaski JC, Elliott PM, Salomone O, Dickinson K, Gordon D, Hann C, Holt DW. Concentration of circulating plasma endothelin in-patients with angina and normal coronary angiograms. British Heart Journal 1995; 74: 620-4.
17. Glazier JJ, Faxon DP, Mills RM, Bresnahan MR, Ryan TJ, Gavras H. Effect of arginine vasopressin on coronary and systemic hemodynamics in man. International Journal of Cardiology 1989; 24: 95-103.
18. Kovanecz I, Papp JG, Szekeres L. Increased cardiac workload by adrenoceptor agonists for the estimation of potential anti-ischemic activity in a conscious rabbit model. Journal of Pharmacological & Toxicological Methods 1997; 37: 149-59.
19. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circulation Research 1980; 47: 1-9.
20. Taira N. Differences in cardiovascular profile among calcium antagonists. American Journal of Cardiology 1987; 59: 24B-29B.
21. Tippins JR, Antoniw JW, Maseri A. Endothelin-1 is a potent constrictor in conductive and resistive coronary arteries. Journal of Cardiovascular Pharmacology 1989; 13 (Supplement 5): S177-S179.
22. Ezra D, Goldstein RE, Czaja JF, Feuerstein GZ. Lethal ischemia due to intracoronary endothelin in pigs. American Journal of Physiology 1989; 257: H339-H343.
23. Kishimoto T, Okamiya Y, Aoki K, Ota M, Hoshina K, Takeshita T. Effect of palonidipine hydrochloride (TC-81), a new dihydropyridine derivative, on various myocardial ischemic models. Folia Pharmacologica Japonica 1993; 102: 85-100. (In Japanese)
24. Boyle WA III, Segel LD. Direct cardiac effects of vasopressin and their reversal by a vascular antagonist. American Journal of Physiology 1986; 251: H734-H741.
25. Hatano N, Nakatsuji K, Nose I, Shimizu M. Effect of antianginal agents on electrocardiographic change induced with vasopressin in rats. Pharmacometrics 1980; 19: 311-7.
26. 1a receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits. Fundamental and Clinical Pharmacology 1995; 9: 17-24.
27. Kugiyama K, Yasue H, Okumura K, Ogawa H, Fujimoto K, Nakao K, Yoshimura M, Motoyama T, Inobe Y, Kawano H. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 1996; 94: 266-71.
28. 2+ channel antagonist, in rats: comparison with nifedipine and amlodipine. European Journal of Pharmacology 1997; 324: 201-4.
29. Sogabe T, Mori T, Ohura M, Tominaga M, Koga K, Yabuuchi Y. Venodilatory effects of pranidipine, a calcium channel blocker, monitored with perfluoro-carbon in vivo 19F-NMR spectroscopy. Magnetic Resonance Imaging 2000; 18: 1101-6.
30. Kato K, Iinuma H, Nakajima M. A clinical effect of pranidipine (OPC-13340) on effort and/or decubitus angina - a multicenter, double-blind, positive-controlled study. Igaku no Ayumi 1994; 170: 971-87. (In Japanese)
31. Mori T, Takeuchi T, Ohura M, Miyakoda G, Fujiki H, Orito K, Yoshida K, Hirano T, Yamamura Y, Sumida T, Nakaya Y, Satake H, Hata F. Pranidipine, a new 1,4-dihydropyridine-calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Molecular and Cellular Biochemistry 1998; 178: 335-43.
32. Mori T, Takase H, Toide K, Hirano T, Kambe T, Nakayama N, Schwartz A. Pranidipine, a 1,4-dihydropyridine calcium channel blocker that enhances nitric oxide-induced vascular relaxation. Cardiovascular Drug Reviews 2001; 19: 1-8.
33. Yang J, Fukuo K, Morimoto S, Niinobu T, Suhara T, Ogihara T. Pranidipine enhances the action of nitric oxide released from endothelial cells. Hypertension 2000; 35: 82-5.